Genomic Medicine Alliance News
- Thursday, 19 February 2015
The Genomic Medicine Alliance has joined this week, as Orgaizational member, the Global Alliance for Genomics and Health.
The Global Alliance for Genomics and Health aims to help accelerate the potential of genomic medicine to advance human health.The Global Alliance works to establish, broadly disseminate, and advocate for the use of interoperable technical standards for managing and sharing genomic and clinical data. At present, the Global Alliance brings together over 220 leading institutions working in healthcare, research, disease advocacy, life science, and information technology that are working together to create a common framework of harmonized approaches to enable the responsible, voluntary, and secure sharing of genomic and clinical data.
By partnering with the Global Alliance, the Genomic Medicine Alliance aims to create synergies for the benefit of its members, particularly from developing countries, where genomics data sharing is still in its infancy.
- Tuesday, 30 December 2014
The Genomic Medicine Alliance proudly announces the publication of the Special Issue with the theme "Public Health Pharmacogenomics", guest edited by Professor George P. Patrinos (University of Patras, Greece) and published by Public Health Genomics, the official journal of the Genomic Medicine Alliance.
Pharmacogenomics has a pivotal role in genomic medicine aiming to delineate drug efficacy and toxicity with the underlying genomic composition in genes involved in the pharmacokinetics and pharmacodynamics of drug regimens. Although there have been major leaps in pharmacogenomic research, facilitated by the genomic technology revolution, the pace of these discoveries have not met with reciprocal advances in the translation of these findings into the clinic, resulting into the personalization of conventional therapeutic interventions. To this end, there are often significant barriers that hamper the smooth incorporation of pharmacogenomics research findings in the daily medical practice, which have to do more with disciplines related to Public Health Genomics rather than pharmacogenomics research itself.
This Special issue is a collection of timely contributions of perspectives and original articles that touch upon pharmacogenomics in relation to Public Health Genomics disciplines, namely ethics in genomics, economic evaluation in genomic medicine, genome informatics and knowledgebases, and the involvement and genetics education of the various stakeholders in the field of pharmacogenomics.
To access the full content of the Special Issue "Public Health Pharmacogenomics", please click here.
- Saturday, 08 November 2014
The Special Issue entitled "Genomic Medicine in 2014", that was encouraged by the Genomic Medicine Alliance and guest edited by Professors George P. Patrinos (University of Patras, Greece) and Barbara Prainsack (Kings College London, UK), members of the Scientific Advisory Committee has been published in Personalized Medicine, an international peer-review journal published by Future Medicine Group.
This Special issue is a collection of original, perspective and review articles highlighting the recent development of Genomic Medicine. This issue also hosts an interview of Professor Vural Ozdemir (Turkey), entitled "Personalized Medicine across borders and without borders". In his inteview Prof. Odzemir indicates that "...Alliances such as the Genomic Medicine Alliance are well poised to deliver on the realistic promises of genomics in the next 5–10 years and perhaps much sooner, in the ‘developed and developing world’ alike, and doing so in the spirit of responsible innovation, whereby ethics research is well informed by the social sciences."
Click here to access the entire content of the Special Issue "Genomic Medicine in 2014"
Click here to read to interview by Professor Vural Ozdemir.
- Thursday, 02 October 2014
The Scientific Advisory Committee decided to add a new Working Group on Rare Diseases and Drug Outcomes to the activities of the Genomic Medicine Alliance. This working group will aim to establish collaborative projects among Genomic Medicine Alliance members to elicudate the genetic basis of rare genetic diseases. Also, in conjunction to the Pharmacogenomics Working Group activities, this new Working Group aspires to engage into collaborative projects to delineate genomic variants with rare drug outcomes.
Activities of this new Working Group will be coordinated by Professor Domenica Taruscio (Rome, Italy), who will also participate in the Scientific Advisory Committee of the Genomic Medicine Alliance.